Last reviewed · How we verify
NCT03375515
PCA vs Non-PCA Intravenous Hydromorphone Titration for Severe Cancer Pain
Phase 3 trial testing Hydromorphone in Cancer Pain in 214 participants. Completed in 10 January 2020.
10 December 2019
Quick facts
| Lead sponsor | Fujian Cancer Hospital |
|---|---|
| Phase | Phase 3 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 214 |
| Start date | 29 September 2018 |
| Primary completion | 10 December 2019 |
| Estimated completion | 10 January 2020 |
| Sites | 1 location across China |
Drugs / interventions tested
- Hydromorphone (HYDROMORPHONE) — full drug profile →
- PCA pump
Conditions studied
- Cancer Pain — all drugs for Cancer Pain →
Sponsor
Fujian Cancer Hospital
Who can join
Adults 18 to 70, any sex, with Cancer Pain. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
A large number of studies have shown that patients feel more satisfied with hydromorphone in the pain management. and a systematic review found that hydromorphone may be better suited than morphine for titration of acute analgesia. However, current researches on intravenous opioid titration for cancer pain such as hydromorphone are relatively insufficient in China. Therefore, a prospective, multi-center, randomized controlled study is conducted to assess the efficacy and safety of comparing patient-controlled analgesia (PCA) versus non-PCA intravenous hydromorphone titration for severe cancer pain.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT03375515
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Hydromorphone
Trials testing the same drug.
- NCT06868589 — Reducing Pain With Methadone and Ketamine in Liver Transplant · Phase 4 · active not recruiting
- NCT06949059 — Intravenous Hydromorphone for the Treatment of Acute Pain · Phase 1, PHASE2 · recruiting
- NCT06525740 — Methadone Versus Intrathecal Hydromorphone for Postoperative Pain Relief in Gynecologic Cancer Undergoing Surgery · Phase 4 · recruiting
- NCT06406400 — Drug-Drug Interaction and Safety of AZD4041 Study (Part 1) and Efficacy, Safety, Pharmacokinetics and Pharmacodynamics o · Phase 1 · terminated
- NCT06411795 — Rectus Sheath Block With Liposomal Bupivacaine Versus Thoracic Epidural Analgesia for Pain Control Following Pancreatodu · Phase 2 · recruiting
Other recruiting trials for Cancer Pain
Currently open trials in the same condition.
- NCT07445386 — Transdiscal vs Paravertebral Neurolytic Splanchnic Nerve Block for Upper Abdominal Cancer Pain · NA · recruiting
- NCT07405645 — Stereotactic MRI-guided Focused Ultrasound Mesencephalotomy · NA · recruiting
- NCT07382297 — Effect of Adding Ultrasound Guided IPACK Block to Adductor Canal Block for Postoperative Pain in Knee Tumor Excision · NA · recruiting
- NCT07318519 — Cognitive Behavioral Theory-assisted Virtual Reality for Chronic CANcer Pain (VR-CAN) · NA · recruiting
- NCT06489769 — Opioid Misuse in Patients with Cancer · recruiting
Other Fujian Cancer Hospital trials
Trials by the same sponsor.
- NCT07470840 — SBRT Plus Anlotinib and Bimepolizumab in Locally Advanced or Metastatic Renal Cell Carcinoma · Phase 2 · not yet recruiting
- NCT07469306 — Short-Course RT Plus CAPOX and Tislelizumab vs Long-Course CRT Plus Tislelizumab for Locally Advanced Rectal Cancer · Phase 2 · not yet recruiting
- NCT07492654 — Clinical Study on the Prevention and Treatment of Radiation Vaginitis With Triethanolamine Cream · Phase 4 · not yet recruiting
- NCT07399158 — CROSSROAD: Treatment Regimen Switch - Re-induction Chemotherapy vs. Direct Radiotherapy in LANPC With Inadequate Respons · not yet recruiting
- NCT07256236 — SKB264 Plus QL1706 in Recurrent or Metastatic Cervical Cancer · Phase 2 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03375515 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Fujian Cancer Hospital
- Last refreshed: 8 March 2021
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03375515.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing